At present, because many solid tumors lack tumor-specific antigens (TSAs), humanized CD19 overexpressing tumor cell lines can be used as a powerful tool and platform to evaluate the superiority of TIL CAR-Ts. This evidence concerns the gene CD19 and neoplasm.